



01-07-02

8700 5165
6410

TRANSMITTAL LETTER

Case No. 8465/20

Serial No. 09/695,237	Filing Date November 26, 2001	Examiner To Be Assigned	Group Art Unit 3763
Inventor(s) Mogensen et al.			
Title of Invention INJECTOR DEVICE FOR PLACING A SUBCUTANEOUS INFUSION SET			

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is A Transmittal Letter (in duplicate); Information Disclosure Statement (in duplicate); Form PTO-1449; and White Acknowledgement Postcard.

Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.

A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.

Petition for a _____ month extension of time.

No additional fee is required.

The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		or	Other Than Small Entity		
Rate	Add'l Fee	Rate	Add'l Fee	Rate	
x \$9 =				x \$18 =	
x 42 =				x \$84 =	
+ \$140 =				+ \$280 =	
	Total add'l fee	\$		Total add'l fee	\$

Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.

A check in the amount of \$_____ to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

David Rozenblat
Registration No. 47,044
Attorney for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail EVO05609875, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on 1/3/2002.

Date: 1/3/2002

Signature:

"Express Mail" mailing label number EV005609875US

Date of Deposit: 1/3/2002



Our Case No.: 8465/20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mogensen et al.

Serial No.: 09/995,237

Filing Date: November 26, 2001

For: INJECTOR DEVICE FOR
PLACING A SUBCUTANEOUS
INFUSION SET

Examiner: To Be Assigned

Group Art Unit No.: 3763

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

U.S. PATENT DOCUMENTS		
No.	Date	Name
5,591,188	01/07/97	Waismann
5,665,071	09/09/97	Wyrick
5,851,197	12/22/98	Marano et al.
6,093,172	7/25/00	Funderburk et al.
6,293,925 B1	9/25/01	Safabash et al.

RECEIVED
JAN 11 2002
TC 3700 MAIL ROOM
TECHNOLOGY CENTER
RECEIVED
APR - 3 2002
RECEIVED
APR - 3 2002

FOREIGN PATENT DOCUMENTS		
No.	Date	Name
WO 99/33504	07/08/99	Safabash et al.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application is a continuation-in-part application of U.S. Serial No. 09/967,400, filed September 28, 2001 and is relied upon for an earlier filing dated under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of documents not previously cited and submitted to the Patent and Trademark Office in the prior application Serial No. 09/967,400 are enclosed for the convenience of the Examiner.

Applicant(s) respectfully request that the listed documents be made of record in
the present case.

Respectfully submitted,



David Rozenblat
Registration No. 47,044
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200